JO
AARD

John Overdeck’s Aardvark Therapeutics AARD Stock Holding History

John Overdeck’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Sell
108,377
-54,978
-34% -$257K ﹤0.01% 3992
2026
Q1 		$616K Buy
163,355
+34,569
+27% +$358K ﹤0.01% 3589
2025
Q4 		$1.69M Buy
128,786
+65,217
+103% +$814K ﹤0.01% 2557
2025
Q3 		$845K Buy
+63,569
New +$717K ﹤0.01% 2689
2025
Q2 		– Sell
-15,424
Closed -$116K – 3648
2025
Q1 		$116K Buy
+15,424
New +$173K ﹤0.01% 2948

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

John Overdeck's AARD Position: Q2 2026 in Review

John Overdeck reduced its Aardvark Therapeutics (AARD) stake by 34% in Q2 2026, selling an estimated $257K and leaving 108,377 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #3992.

John Overdeck first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.69M in Q4 2025. 72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • John Overdeck held 108,377 shares of Aardvark Therapeutics worth $624K as of Q2 2026.
  • John Overdeck sold 54,978 Aardvark Therapeutics shares in Q2 2026, an estimated $257K.
  • Aardvark Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3992 holding.
  • John Overdeck first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • John Overdeck's Aardvark Therapeutics position peaked at $1.69M in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.